

Special Issue

Engineering Cells for Immunotherapy

Message from the Guest Editor

This Special Issue, "Engineering Cells for Immunotherapy", aims to spotlight recent advances in cell engineering strategies that enhance the effectiveness of immunotherapy against cancers and other diseases. This collection will include research on genetically modifying immune cells, such as CAR T cells, to improve their targeting and destruction of tumor cells, as well as techniques to enhance their persistence and functionality in the human body. Additionally, it will explore the integration of biomaterials, delivery systems, and synthetic biology tools that optimize the therapeutic potential and precision of engineered immune cells. By addressing both preclinical and clinical developments, the Special Issue will provide a comprehensive view of how engineering cells at the molecular and cellular levels can lead to innovative therapies with greater efficacy and fewer side effects. This initiative invites multidisciplinary contributions that intersect molecular biology, bioengineering, materials science, and clinical applications to provide a holistic approach to cell-based immunotherapies.

Guest Editor

Dr. Yun Chang

Department of Biomedical Engineering, Hong Kong Polytechnic University, Hong Kong, China

Deadline for manuscript submissions

closed (30 April 2025)



Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



mdpi.com/si/223083

Bioengineering
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
bioengineering@mdpi.com

[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)





Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed



[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, Inspec, and other databases.

Journal Rank:

JCR - Q2 (Engineering, Biomedical) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.